Progress in the Correlation Between Inflammasome NLRP3 and Liver Fibrosis

Overview

Journal J Clin Transl Hepatol

Specialty Gastroenterology

Date 2024 Feb 12

PMID 38343611

Authors

Meihua Sun

Yanqing Zhang

Anbing Guo

Zongting Xia

Lijun Peng

Affiliations

Soon will be listed here.

Abstract

Liver fibrosis is a reversible condition that occurs in the early stages of chronic liver disease. To develop effective treatments for liver fibrosis, understanding the underlying mechanism is crucial. The NOD-like receptor protein 3 (NLRP3) inflammasome, which is a part of the innate immune system, plays a crucial role in the progression of various inflammatory diseases. NLRP3 activation is also important in the development of various liver diseases, including viral hepatitis, alcoholic or nonalcoholic liver disease, and autoimmune liver disease. This review discusses the role of NLRP3 and its associated molecules in the development of liver fibrosis. It also highlights the signal pathways involved in NLRP3 activation, their downstream effects on liver disease progression, and potential therapeutic targets in liver fibrosis. Further research is encouraged to develop effective treatments for liver fibrosis.

Citing Articles

Cytoskeleton Remodeling-Related Proteins Represent a Specific Salivary Signature in PSC Patients.

Ceccherini E, Morlando A, Norelli F, Coco B, Bellini M, Brunetto M Molecules. 2024; 29(23).

PMID: 39683940 PMC: 11643721. DOI: 10.3390/molecules29235783.

Neutrophil extracellular traps facilitate liver inflammation/fibrosis progression by entering macrophages and triggering AIM2 inflammasome-dependent pyroptosis.

Zhang Y, Wu R, Zhan X, Wang X, Xiang L, Duan Y Cell Commun Signal. 2024; 22(1):556.

PMID: 39568027 PMC: 11577833. DOI: 10.1186/s12964-024-01944-9.

Tonabersat suppresses priming/activation of the NOD-like receptor protein-3 (NLRP3) inflammasome and decreases renal tubular epithelial-to-macrophage crosstalk in a model of diabetic kidney disease.

Cliff C, Squires P, Hills C Cell Commun Signal. 2024; 22(1):351.

PMID: 38970061 PMC: 11225428. DOI: 10.1186/s12964-024-01728-1.

References

Kisseleva T, Brenner D . Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2020; 18(3):151-166. DOI: 10.1038/s41575-020-00372-7. View

Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal W, Strowig T . Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012; 482(7384):179-85. PMC: 3276682. DOI: 10.1038/nature10809. View

Hoyt L, Randall M, Ather J, DePuccio D, Landry C, Qian X . Mitochondrial ROS induced by chronic ethanol exposure promote hyper-activation of the NLRP3 inflammasome. Redox Biol. 2017; 12:883-896. PMC: 5413213. DOI: 10.1016/j.redox.2017.04.020. View

Jiang S, Zhang Y, Zheng J, Li X, Yao Y, Wu Y . Potentiation of hepatic stellate cell activation by extracellular ATP is dependent on P2X7R-mediated NLRP3 inflammasome activation. Pharmacol Res. 2016; 117:82-93. DOI: 10.1016/j.phrs.2016.11.040. View

Hornung V, Bauernfeind F, Halle A, Samstad E, Kono H, Rock K . Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008; 9(8):847-56. PMC: 2834784. DOI: 10.1038/ni.1631. View

Zhong Z, Liang S, Sanchez-Lopez E, He F, Shalapour S, Lin X . New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature. 2018; 560(7717):198-203. PMC: 6329306. DOI: 10.1038/s41586-018-0372-z. View

Liu H, Zhan X, Xu G, Wang Z, Li R, Wang Y . Cryptotanshinone specifically suppresses NLRP3 inflammasome activation and protects against inflammasome-mediated diseases. Pharmacol Res. 2020; 164:105384. DOI: 10.1016/j.phrs.2020.105384. View

Hu J, Wang H, Li X, Liu Y, Mi Y, Kong H . Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder. Theranostics. 2020; 10(21):9702-9720. PMC: 7449923. DOI: 10.7150/thno.44297. View

Wu S, Wen F, Zhong X, Du W, Chen M, Wang J . Astragaloside IV ameliorate acute alcohol-induced liver injury in mice modulating gut microbiota and regulating NLRP3/caspase-1 signaling pathway. Ann Med. 2023; 55(1):2216942. PMC: 10228327. DOI: 10.1080/07853890.2023.2216942. View

10.

Wree A, Eguchi A, McGeough M, Pena C, Johnson C, Canbay A . NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology. 2013; 59(3):898-910. PMC: 4008151. DOI: 10.1002/hep.26592. View

11.

Mridha A, Wree A, Robertson A, Yeh M, Johnson C, Van Rooyen D . NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017; 66(5):1037-1046. PMC: 6536116. DOI: 10.1016/j.jhep.2017.01.022. View

12.

de Carvalho Ribeiro M, Szabo G . Role of the Inflammasome in Liver Disease. Annu Rev Pathol. 2021; 17:345-365. PMC: 10501045. DOI: 10.1146/annurev-pathmechdis-032521-102529. View

13.

Pan H, Jian Y, Wang F, Yu S, Guo J, Kan J . NLRP3 and Gut Microbiota Homeostasis: Progress in Research. Cells. 2022; 11(23). PMC: 9739202. DOI: 10.3390/cells11233758. View

14.

Cortez-Pinto H, Carneiro de Moura M, Day C . Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol. 2005; 44(1):197-208. DOI: 10.1016/j.jhep.2005.09.002. View

15.

Hou L, Yang L, Chang N, Zhao X, Zhou X, Dong C . Macrophage Sphingosine 1-Phosphate Receptor 2 Blockade Attenuates Liver Inflammation and Fibrogenesis Triggered by NLRP3 Inflammasome. Front Immunol. 2020; 11:1149. PMC: 7333785. DOI: 10.3389/fimmu.2020.01149. View

16.

Akbal A, Dernst A, Lovotti M, Mangan M, McManus R, Latz E . How location and cellular signaling combine to activate the NLRP3 inflammasome. Cell Mol Immunol. 2022; 19(11):1201-1214. PMC: 9622870. DOI: 10.1038/s41423-022-00922-w. View

17.

Zhao Y, Wang Z, Feng D, Zhao H, Lin M, Hu Y . p66Shc Contributes to Liver Fibrosis through the Regulation of Mitochondrial Reactive Oxygen Species. Theranostics. 2019; 9(5):1510-1522. PMC: 6401497. DOI: 10.7150/thno.29620. View

18.

Ludwiczek O, Kaser A, Novick D, Dinarello C, Rubinstein M, Vogel W . Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease. J Clin Immunol. 2002; 22(6):331-7. DOI: 10.1023/a:1020600230977. View

19.

Hou Y, He H, Ma M, Zhou R . Apilimod activates the NLRP3 inflammasome through lysosome-mediated mitochondrial damage. Front Immunol. 2023; 14:1128700. PMC: 10285205. DOI: 10.3389/fimmu.2023.1128700. View

20.

Torres S, Segales P, Garcia-Ruiz C, Fernandez-Checa J . Mitochondria and the NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis. Cells. 2022; 11(9). PMC: 9105698. DOI: 10.3390/cells11091475. View